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Abstract: Sporadic occurrence of juvenile-onset necrotizing encephalopathy (SNE) has been previously
reported in Yorkshire terriers. However, so far, no causative genetic variant has been found for
this breed-specific form of suspected mitochondrial encephalomyopathy. Affected dogs showed
gait abnormalities, central visual defects, and/or seizures. Histopathological analysis revealed the
presence of major characteristics of human Leigh syndrome and SNE in Alaskan huskies. The aim of
this study was to characterize the genetic etiology of SNE-affected purebred Yorkshire terriers. After
SNP genotyping and subsequent homozygosity mapping, we identified a single loss-of-function
variant by whole-genome sequencing in the canine SLC19A3 gene situated in a 1.7 Mb region of
homozygosity on chromosome 25. All ten cases were homozygous carriers of a mutant allele, an indel
variant in exon 2, that is predicted to lead to a frameshift and to truncate about 86% of the wild type
coding sequence. This study reports a most likely pathogenic variant in SLC19A3 causing a form of
SNE in Yorkshire terriers and enables selection against this fatal neurodegenerative recessive disorder.
This is the second report of a pathogenic alteration of the SLC19A3 gene in dogs with SNE.
Keywords: Canis familiaris; whole-genome sequencing; rare disease; precision medicine;
neurometabolic disorder
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1. Introduction
Subacute necrotizing encephalomyelopathy (SNE), also termed Leigh syndrome (LS; OMIM
256000) represents a devastating neurodegenerative disorder in people, characterized by a wide
variety of clinical signs, ranging from severe neurologic problems to a near absence of abnormalities
with the central nervous system most frequently affected [1]. Originally, Archibald Denis Leigh,
a British neuropsychiatrist described the condition in 1951 [2]. SNE is characterized by focal and
bilaterally symmetrical, necrotic lesions involving the thalamus, brainstem, and posterior columns of
the spinal cord [3]. In SNE, various mutations in mitochondrial respiratory chain complexes lead to
the disruption of ATP synthesis resulting in the characteristic pathology of SNE [4]. Mitochondrial
encephalomyelopathies, such as SNE or LS, represent rare inherited neurometabolic disorders showing
considerable genetic heterogeneity and associated pathogenic variants affecting over 85 different genes
of the mitochondrial or nuclear genome [3]. Therefore, they represent mitochondrial disorders with
the largest genetic heterogeneity [1].
As human SNE is rare and heterogeneous, studying domestic animal species showing resembling
conditions might add to the understanding of such a complex group of disorders. Rare forms of SNE
were described e.g., in cattle [5–7] and dogs (OMIA 001097-9615). The first report of this disorder
was described in Alaskan huskies [8,9] and subsequently, a similar form of SNE was reported in
Yorkshire terriers [10] and American Staffordshire bull terriers [11]. Neuropathologically, SNE in
Yorkshire terriers is nearly identical to the Alaskan husky form and very similar to human Leigh
syndrome [10]. An initial genetic investigation of SNE-affected Yorkshire terriers revealed no indication
for disease-causing variants in the mitochondrial genome [10], whereas more recently in Alaskan
huskies the pathogenesis of recessively inherited SNE was unraveled [12,13]. This breed-specific
fatal brain disorder in Alaskan huskies is associated with a deleterious loss-of-function variant in
SLC19A3 encoding for a thiamine transporter 2 (THTR2) with a predominately central nervous system
(CNS) distribution [12,13]. The SLC19A3 gene product controls the uptake of thiamine in the CNS
via expression of the thiamine transporter protein THTR2. Pathogenic variants are associated with
thiamine metabolism dysfunction syndrome-2 in people (THMD2; OMIM 607483), also known as
biotin-responsive basal ganglia disease (BBGD) or thiamine-responsive encephalopathy [14]. This
SLC19A3–related condition is an autosomal recessive disorder with childhood-onset that presents
as a subacute encephalopathy and progresses to severe cogwheel rigidity, dystonia, quadriparesis,
and eventually death if left untreated (OMIM 606152). The SLC19A3–related SNE of Alaskan huskies
was proposed as a possible large animal model that may allow prospective investigations into the
mechanisms of SLC19A3-related syndromes and the potential role of thiamine and/or biotin as a
therapeutic strategy [12,13].
To elucidate the disease mechanism underlying monogenic autosomal recessive inherited SNE
in Yorkshire terriers, we applied homozygosity mapping and whole-genome sequencing revealing a
most likely pathogenic variant in the canine SLC19A3 gene.
2. Materials and Methods
2.1. Ethics Statement
All animal experiments were performed according to the local regulations. All animals in this
study were examined with the consent of their owners. Sample collection was approved by the
Cantonal Committee for Animal Experiments (Canton of Bern; permit 71/19).
2.2. Animals
In total, 172 blood samples of Yorkshire terriers were collected. Ten dogs were diagnosed with
Leigh-like subacute necrotizing encephalopathy (SNE) according to Baiker et al. [10]. These affected
dogs were unrelated, apart from two full siblings for which their sire and dam (obligate carriers) as
well as a single normal littermate were also available. The remaining 159 dogs represented unrelated
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purebred controls. Genomic DNA was isolated from EDTA blood samples using the Maxwell RSC
Whole Blood DNA kit (Promega, Dübendorf, Switzerland).
2.3. Single Nucleotide Polymorphism Array Genotyping
Four selected SNE-affected Yorkshire terriers were genotyped on Illumina CanineHD BeadChip
array (Illumina, San Diego, CA, USA). PLINK v1.9 [15] was used to perform the quality control filtering
steps of the obtained genotyping data and the subsequent homozygosity analysis. Single nucleotide
polymorphisms (SNP) with a call rate <90% were removed leaving 167,185 markers. All individuals
had call rates >90%. Homozygosity analysis was carried out with PLINK v1.9 [15] to determine
intervals of extended homozygous regions with alleles shared by all four affected dogs.
2.4. Whole-Genome Sequencing
Whole-genome sequence (WGS) data of a single affected dog was obtained at 19.7× coverage
in order to identify the causative variant for SNE. The sequence data analysis and calling of single
nucleotide variants and small indels (SNVs) including the prediction of functional effects were
described before [16]. The dog reference genome assembly CanFam3.1 and NCBI annotation release
105 was used. Additionally, a publicly available control genomes cohort of 720 dogs from 130 various
breeds, and 9 wolves [16] was used to filter variants private in the sequenced SNE-affected dog; this
also included 60 unrelated Yorkshire terriers (Supplementary Table S1). The Integrative genomics
viewer (IGV) software [17] was used for visual inspection and screening for structural variants in the
associated regions.
2.5. Sanger Sequencing and Targeted Genotyping
Polymerase chain reaction (PCR) and Sanger sequencing were used to validate and characterize the
SLC19A3 indel variant (XM_022409850.1:c.205_210delins35) identified from whole-genome sequencing.
PCR primers were designed using primer 3 [18]. PCR products from genomic DNA were amplified using
AmpliTaqGold360 MasterMix (Thermo Fisher Scientific, Waltham, MA, USA) and the purified PCR
amplicons were directly sequenced on an ABI3730 capillary sequencer (Thermo Fisher Scientific) using
the following primers: GGCAGTCACCATCCCATAGA (forward) and GATATTGGGCAAGCCACCTA
(reverse) generating 309 bp products. The sequence data were analyzed with Sequencher 5.1 software
(GeneCodes, Ann Arbor, MI, USA). Diagnostic genotyping was performed by fragment length analysis
using a different forward primer (ATCCCTTGCAGGATGATGAC) to produce amplicons of 218 bp
or 247 bp representing the wild type or variant allele, respectively. The 29 bp size difference was
visualized on a Fragment Analyzer capillary gel electrophoresis instrument (Advanced Analytical
Technologies, Ames, IA, USA).
2.6. Availability of Data and Material
The whole-genome data of an SNE-affected Yorkshire terrier are freely available at the European
Nucleotide Archive (ENA) under sample accession number SAMEA3928145. All accession numbers of
the used control genomes are available in Supplementary Table S1.
All genome positions are reported with respect to dog reference genome assembly CanFam3.1 and
NCBI annotation release 105. All references to the canine SLC19A3 gene correspond to the accessions
NC_006607.3 (NCBI accession), XM_022409850.1 (mRNA), and XP_022265558.1 (protein).
3. Results
3.1. Homozygosity Analysis
Based on the clinicopathological diagnosis of Leigh-like subacute necrotizing encephalopathy
(SNE) in all examined Yorkshire terriers and the similarities to the recessively inherited conditions in
SNE-affected Alaskan husky dogs and THMD2-affected humans, as well as the available pedigree
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information of the two SNE-affected siblings, a recessive mode of inheritance was postulated. Therefore,
homozygosity mapping assuming identity-by-descent (IBD) was used to determine critical genomic
regions shared across four SNP array genotyped cases. This revealed five genome regions with a total
of ~4.1 Mb located on five different dog chromosomes (Table 1), representing 0.17% of the canine
reference sequence. Visual inspection of these regions in the WGS of the affected dog did not reveal
any evidence for copy number variants or large structural rearrangements.
Table 1. Regions of shared homozygosity detected in four subacute necrotizing encephalomyelopathy
(SNE)-affected Yorkshire terriers.
Chromosome
Position 1 Length (kb) Number of Annotated
Protein-Coding Genes in the RegionStart End
3 44,184,889 44,286,148 101.3 0
6 71,329,720 71,552,171 222.5 1
10 20,608,121 22,376,735 1768.6 22
25 39,477,619 41,191,570 1714.0 13
31 33,337,422 33,591,249 253.8 2
1 in respect to dog reference genome assembly CanFam3.1.
3.2. Identification of the Causative Variant
Filtering the variants of a single affected Yorkshire terrier against 729 public control genomes [16],
including 60 breed controls, for single-nucleotide variants (SNVs) and short indels present in the five
identified IBD-regions resulted in only a single private protein-changing variant (Figure 1a). The indel
affecting ~45 bp is located in exon 2 of the thiamine transporter 2 (LOC486151) gene, also known as solute
carrier family 19 members 3 (SLC19A3) gene (Figure 1b). PCR and subsequent Sanger sequencing
confirmed the homozygous presence of this small structural variant in SNE-affected Yorkshire terriers
and revealed the detailed features of the indel: a 35 bp insertion replacing 6 bp and thereby disturbing
the correct reading frame (Figure 1c). There are 15 currently annotated transcript isoforms for the canine
SLC19A3, which is in reverse complementary orientation with respect to the canine reference genome.
While the canine SLC19A3 protein length is 495 amino acids, the human protein (NP_001358340.1)
has 496 amino acids, from which 408 (82.3%) are identical between dog and human. The Yorkshire
terrier variant leads to a frameshift and a premature stop codon (c.205_210delins35; p.Pro69Ilefs*45)
truncating ~86% of the wild type coding sequence (Figure 1c).
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that the number of 5′-untranslated exons (grey) varies between transcript isoforms, whereas the five 
protein-coding 3′-exons (black) are more conserved; (c) Sanger sequencing electropherograms 
illustrate sequences of a homozygous SNE-affected Yorkshire terrier, a heterozygous carrier, and a 
homozygous wild type dog. The red arrows indicate that the 35 bases shown in red are inserted, 
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the reading frame altering the amino acid sequence of the SLC19A3 protein and leading to a 
premature stop is shown above. 
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3.3. Targeted Genotyping of the Variant
Genotyping by fragment size analysis of the 172 available Yorkshire terriers confirmed perfect
segregation of the detected SLC19A3 variant with the observed disease phenotype. Only the ten
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SNE-affected dogs were homozygous for the variant allele (Table 2). Two obligate carriers and one tested
normal littermate were heterozygous carriers of the variant, while 162 controls tested homozygous for
the wild type allele (Table 2).
Table 2. Segregation of the SLC19A3: c.205_210delins35 genotypes with subacute necrotizing
encephalopathy in Yorkshire terriers.
SNE Status wt/wt wt/var var/var
Affected (n = 10) 0 0 10
Non-affected (n = 222) 1 219 3 2 0
1 including 60 dogs with WGS data 2 includes 2 obligate carriers and 1 normal littermate of the affected dogs.
4. Discussion
In this study, the obtained genetic results elucidate the underlying aetiology of the previous
clinical and pathological characterization of a Leigh-like subacute necrotizing encephalopathy in the
affected Yorkshire terriers, which resembles the human Leigh syndrome. The SLC19A3 variant found
by a combination of SNP genotyping-based homozygosity mapping and whole-genome sequencing,
confirmed by Sanger sequencing, segregated perfectly in the investigated cohort of >200 unrelated
Yorkshire terriers.
Numerous homozygous as well as compound heterozygous variants have been reported before
in different regions of SLC19A3 in human patients suffering from thiamine metabolism dysfunction
syndrome-2 [19]. SLC19A3 is a member of solute carrier family 19 and encodes thiamine transporter
2. Together with thiamine transporter 1, it is necessary for transport and homeostasis of thiamine
that is important in brain development. [20]. Slc19a3-knockout mice showed progressive wasting and
lethargy leading to a premature death as well as a significant decrease in thiamin uptake, even though
there were no obvious histological changes in the brain [21].
The herein-described most likely pathogenic variant (XP_022265558.1:p.Pro69Ilefs*45) lies within
the second of 12 transmembrane domains of the SLC19A3 protein and, therefore, affects ~86% of the
wild type sequence. The SLC19A3 gene probability of loss-of-function intolerance is pLI = 0.104 [22],
which indicates variants in SLC19A3 leading to a loss of gene function are most likely recessive, where
loss of a single copy is often tolerated but the loss of both copies is not. The herein-described variant
leads to an insertion of a premature termination in the second out of five coding exons, suggesting
that any synthesized mRNA would likely be degraded through nonsense-mediated decay, unlikely to
produce a fully functional protein. Heterozygous carriers did not show a visible clinical phenotype, as
they can most likely compensate due to the presence of the normal protein, albeit at a decreased amount.
In conclusion, our results provide strong evidence for a breed-specific deleterious variant in
SLC19A3 as the most likely genetic cause of monogenic autosomal recessive Leigh-like subacute
necrotizing encephalopathy in Yorkshire terriers, and they enable the development of a genetic
test for veterinary diagnostic and breeding decisions. Finally, this presents the second, most likely
breed-specific pathogenic variant in the canine SLC19A3 gene in SNE-affected dogs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/10/1215/s1,
Table S1: Accession numbers of 721 dog and 9 wolf whole-genome genome sequences.
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